- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01032135
Adaptive Treatment for Alcohol and Cocaine Dependence
Primary objective #1: Determine the relative effectiveness of MI-IOP and MI-PC in the full study sample with regard to treatment engagement over weeks 1-12 and cocaine/alcohol use over weeks 1-24.
- Hypothesis 1: An intervention that explores several possible treatment options with the patient and provides the chosen option (e.g., MI-PC) will produce higher rates of treatment engagement than an intervention focused on engagement in IOP only (e.g., MI-IOP).
- Hypothesis 2: An intervention that explores several possible treatment options with the patient and provides the chosen option (e.g., MI-PC) will produce better cocaine/alcohol use outcomes than an intervention focused on engagement in IOP only (MI-IOP).
- Secondary analysis 1: Among the Non-engaged patients, determine rates of selection of each of the three options in MI-PC, retention rates within each option, and cocaine/alcohol use outcomes in each option.
- Secondary analysis 2: Among the Engaged patients, determine rates of selection of each of the three options in MI-PC, retention rates within each option, and cocaine/alcohol use outcomes in each option.
Primary objective #2: Determine whether the relative effectiveness of MI-IOP and MI-PC varies as a function of engagement group, with regard to treatment engagement over weeks 1-12 and cocaine/alcohol use outcomes over weeks 1-24.
- Hypothesis 1: The predicted main effect on retention favoring MI-PC over MI-IOP will be significantly larger among patients in the Non-engaged group than among those in the Engaged group.
- Hypothesis 2: The predicted main effect on cocaine/alcohol use outcomes favoring MI-PC over MI-IOP will be significantly larger among patients in the Non-engaged group than among those in the Engaged group.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
3. Secondary objective #1: Examine outcomes on three secondary measures: percent days abstinent from all substances, negative consequences of drug use, and HIV high risk behaviors.
Hypothesis 1: Outcomes on the secondary measures will be better in MI-PC than in MI-IOP.
4. Secondary objective #2: Test hypotheses concerning potential mediators of the predicted main effect favoring MI-PC over MI-IOP.
Hypothesis 1: The predicted advantage of MI-PC over MI-IOP will be mediated by greater increases in motivation, self-efficacy, commitment to abstinence, and self-help involvement in MI-PC.
5. Secondary objective #3: Test hypotheses concerning effect of additional MI intervention after initial non-engagement persists through 12 weeks.
- Hypothesis 1: A second telephone MI intervention will produce higher rates of subsequent engagement and less cocaine use than no further MI.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Presbyterian Medical Center
-
Philadelphia, Pennsylvania, Forente stater, 19123
- NorthEast Treatment Center
-
Philadelphia, Pennsylvania, Forente stater, 19104
- VAMC
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- meet DSM-IV criteria for lifetime cocaine or alcohol dependence and have used cocaine or alcohol in the prior 6 months;
- be > 18 years of age;
- be judged clinically appropriate for IOP (e.g., no current psychotic disorder or evidence of severe dementia, and no acute medical problem requiring inpatient treatment;
- have no regular IV heroin use during the past year;
- have access to a telephone;
- be willing to be randomized and participate in research; and
- no current participation in methadone or other forms of DA treatment, other than IOP. Finally, because of study follow-up requirements, subjects will
- be required to be metropolitan area residents, and
- be able to provide the name, verified telephone number, and address of at least two contacts who can provide locator information on the patient during follow-up. We will include patients with dependence on other substances, provided that they are cocaine dependent and meet other inclusion criteria.
Exclusion Criteria:
- have a current psychotic disorder (as assessed with the psychotic screen from the MINI) or evidence of dementia severe enough to prevent participation in outpatient treatment;
- have acute medical problem requiring immediate inpatient treatment; or
- are currently participating in methadone or other forms of DA treatment, other than IOP.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: 1-MI-IOP Engaged
Randomized to treatment as usual, and they attend regularly but dropped out of treatment after randomization.
|
2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Andre navn:
|
|
Eksperimentell: 2-MI-IOP Non-Engaged
Randomized to treatment as usual, and do not attend.
|
2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Andre navn:
one telephone counseling session per week for 10 weeks.
Andre navn:
One CBT session per week, for 10 weeks.
Andre navn:
Prescription for naltrexone
Andre navn:
Return to IOP, group therapy 3 times weekly for about three hours a day.
Andre navn:
|
|
Aktiv komparator: 3-MI-PC Engaged
Randomized to treatment choice, but remain attending treatment as usual then dropped out of treatment after randomization.
|
2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Andre navn:
one telephone counseling session per week for 10 weeks.
Andre navn:
One CBT session per week, for 10 weeks.
Andre navn:
|
|
Eksperimentell: 4-MI-PC Non-engaged
Randomized to treatment choice, and do not attend treatment as usual, so the choice option is used.
|
2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
Andre navn:
one telephone counseling session per week for 10 weeks.
Andre navn:
One CBT session per week, for 10 weeks.
Andre navn:
Prescription for naltrexone
Andre navn:
Return to IOP, group therapy 3 times weekly for about three hours a day.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Treatment Engagement
Tidsramme: weeks 3 - 12
|
Number of treatment sessions attended
|
weeks 3 - 12
|
|
Treatment Engagement for Participants Engaged at 2 Weeks, But Disengage Before 8 Weeks
Tidsramme: weeks 9 - 12
|
Number of treatment sessions attended
|
weeks 9 - 12
|
|
Treatment Engagement of Those Non-engaged at 2 Weeks and at 8 Weeks
Tidsramme: weeks 9 - 12
|
Number of treatment sessions attended
|
weeks 9 - 12
|
|
Any Drinking Days in Previous Month
Tidsramme: Month 2 (weeks 5 - 8 post baseline)
|
Days of any drinking in previous month, as reported on Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample drank in the follow up period.
|
Month 2 (weeks 5 - 8 post baseline)
|
|
Any Drinking Days in Previous Month
Tidsramme: Month 3 (weeks 9 - 12 post baseline)
|
Any drinking days during previous month, as reported on Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample drank in the follow up period.
|
Month 3 (weeks 9 - 12 post baseline)
|
|
Any Drinking
Tidsramme: Month 4 (weeks 13 - 15 post baseline)
|
Any drinking at follow up, as reported on Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample drank in the follow up period.
|
Month 4 (weeks 13 - 15 post baseline)
|
|
Any Drinking
Tidsramme: Month 5 (weeks 16 - 20 post baseline)
|
Any drinking at follow up, as reported on Time Line Follow Back, This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample drank in the follow up period.
|
Month 5 (weeks 16 - 20 post baseline)
|
|
Any Drinking
Tidsramme: Month 6 (weeks 21 - 24 post baseline)
|
Any drinking at follow up, as reported on Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample drank in the follow up period.
|
Month 6 (weeks 21 - 24 post baseline)
|
|
Percent Days Drinking
Tidsramme: Month 2 (weeks 5 - 8 post baseline)
|
Percent days of any drinking at follow up, from Time Line Follow Back
|
Month 2 (weeks 5 - 8 post baseline)
|
|
Percent Days Drinking
Tidsramme: Month 3 (weeks 9 - 12 post baseline)
|
Percent days of any drinking at follow up, from Time Line Follow Back
|
Month 3 (weeks 9 - 12 post baseline)
|
|
Percent Days Drinking
Tidsramme: Month 4 (weeks 13 - 16 post baseline)
|
Percent days of any drinking at follow up, from Time Line Follow Back
|
Month 4 (weeks 13 - 16 post baseline)
|
|
Percent Days Drinking
Tidsramme: Month 5 (weeks 17 - 20 post baseline)
|
Percent days of any drinking at follow up, fromTime Line Follow Back
|
Month 5 (weeks 17 - 20 post baseline)
|
|
Percent Days Drinking
Tidsramme: Month 6 (weeks 21 - 24)
|
Percent days of any drinking at follow up, from Time Line Follow Back
|
Month 6 (weeks 21 - 24)
|
|
Any Heavy Drinking Days
Tidsramme: Month 2 (weeks 5 - 8 post baseline)
|
days of five or more drinks per drinking day for men, four or more drinks per drinking day for women, at follow up, from Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of heavy drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample engaged in heavy drinking in the follow up period.
|
Month 2 (weeks 5 - 8 post baseline)
|
|
Any Heavy Drinking Days
Tidsramme: Month 3 (weeks 9 - 12 post baseline)
|
five or more drinks per drinking day for men, four or more drinks per drinking day for women, at follow up, from Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of heavy drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample engaged in heavy drinking in the follow up period.
|
Month 3 (weeks 9 - 12 post baseline)
|
|
Any Heavy Drinking Days
Tidsramme: Month 4 (weeks 13 - 16 post baseline)
|
five or more drinks per drinking day for men, four or more drinks per drinking day for women at follow up, from Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of heavy drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample engaged in heavy drinking in the follow up period.
|
Month 4 (weeks 13 - 16 post baseline)
|
|
Any Heavy Drinking Days
Tidsramme: Month 5 (weeks 17 to 20 post baseline)
|
five or more drinks per day for men, four or more drinks per day for women, from Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of heavy drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample engaged in heavy drinking in the follow up period.
|
Month 5 (weeks 17 to 20 post baseline)
|
|
Any Heavy Drinking Days
Tidsramme: Month 6 (weeks 21 - 24 post baseline)
|
five or more drinks per day for men, four or more drinks per day for women, from Time Line Follow Back.
This is a dichotomous measure, so the means that are reported are the percentage of people who have had any days of heavy drinking during the follow up period specified.
In other words, 0.57 indicates that 57% of the sample engaged in heavy drinking in the follow up period.
|
Month 6 (weeks 21 - 24 post baseline)
|
|
Percent Days Heavy Drinking
Tidsramme: Month 2 (weeks 5 - 8 post baseline)
|
Percent days heavy drinking at follow up, from Time Line Follow Back *heavy drinking is defined as five or more drinks per day for men, four or more for women |
Month 2 (weeks 5 - 8 post baseline)
|
|
Percent Days Heavy Drinking
Tidsramme: Month 3 (weeks 9 - 12 post baseline)
|
Percent days heavy drinking at follow up, from Time Line Follow Back * heavy drinking is defined as five or more drinks per day for men, four or more for women. |
Month 3 (weeks 9 - 12 post baseline)
|
|
Percent Days Heavy Drinking
Tidsramme: Month 4 (weeks 13 - 16 post baseline)
|
Percent days heavy drinking at follow up, from Time Line Follow Back *heavy drinking is defined as five or more drinks per drinking day for men, four or more for women |
Month 4 (weeks 13 - 16 post baseline)
|
|
Percent Days Heavy Drinking
Tidsramme: Month 5 ( weeks 17 - 20 post baseline)
|
Percent days heavy drinking at follow up, from Time Line Follow Back * heavy drinking is defined as five or more drinks per drinking day for men, four or more for women |
Month 5 ( weeks 17 - 20 post baseline)
|
|
Percent Days Heavy Drinking
Tidsramme: Month 6 (weeks 21 - 24 post baseline)
|
Percent days heavy drinking at follow up, from Time Line Follow Back *heavy drinking is defined as five or more drinks per drinking day for men, four or more for women |
Month 6 (weeks 21 - 24 post baseline)
|
|
Any Cocaine Use
Tidsramme: Month 3 (weeks 9 - 12 post baseline)
|
Any cocaine using self report, binary measure of percent days cocaine use.
|
Month 3 (weeks 9 - 12 post baseline)
|
|
Any Cocaine Use
Tidsramme: Month 4 (weeks 13 - 16 post baseline)
|
Any cocaine using self report, binary measure of percent days cocaine use
|
Month 4 (weeks 13 - 16 post baseline)
|
|
Any Cocaine Use
Tidsramme: Month 5 (weeks 17 - 20 post baseline)
|
Any cocaine using self report, binary measure of percent days cocaine use
|
Month 5 (weeks 17 - 20 post baseline)
|
|
Any Cocaine Use
Tidsramme: Month 6 (weeks 21 - 24 post baseline)
|
Any cocaine using self report, binary measure of percent days cocaine use
|
Month 6 (weeks 21 - 24 post baseline)
|
|
Percent Days Cocaine Use
Tidsramme: Month 3 (weeks 9 - 12 post baseline)
|
Percent days of any cocaine use, self reported
|
Month 3 (weeks 9 - 12 post baseline)
|
|
Percent Days Cocaine Use
Tidsramme: Month 5 (weeks 17 - 20 post baseline)
|
Percent days of any cocaine use, self reported
|
Month 5 (weeks 17 - 20 post baseline)
|
|
Percent Days Cocaine Use
Tidsramme: Month 6 (weeks 21 - 24 post baseline)
|
Percent days of any cocaine use, self reported
|
Month 6 (weeks 21 - 24 post baseline)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: James R. McKay, Ph.D, University of Pennsylvania
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 807092
- IND: 101,486
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .